Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in Advanced and Metastatic Breast Cancer
NCT03562390Phase 2Unknown
- Sponsor
- Liaoning Medical Center
- Start
- Apr 2017
- Primary completion
- Jan 2020
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in breast cancer, sponsored by Liaoning Medical Center. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03562390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562390.